Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Emerging
Primary summary from verified readiness
- Confidence
- 66% · stale
- Computed at
- 2026-09-30T22:21:41.482047+00:00
- Claimed
- 35
- Reported
- 20
- Verified
- 20
- Gap
- +15
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Weak
Decision
What the current evidence supports
Agent-assisted assessment · independently reviewed · 2026-09-30
Treat foselutoclax as an investigational retinal-disease candidate.
- Why
- Human studies provide limited safety and biological signals, but Phase 2b missed its primary endpoint and the sponsor dissolved.
- Next
- Reassess if a successor sponsor establishes a funded program and produces confirmatory controlled efficacy and safety results.
Constraints
Blockers
- Prespecified Phase 2b primary endpoint was missed
- Therapeutic efficacy remains unconfirmed
- Small studies limit safety conclusions
- Sponsor dissolved
- No confirmed funded successor development program
- Requires further clinical development and regulatory approval
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 12
- Tier 1
- 3
- Tier 2
- 4
- Tier 3
- 5
- Supports
- 4
- Contradicts
- 7
- Context
- 1
- Latest observed
- 2025-09-26
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 3
- 2026-07-19 Reading moved from unknown to unknown.
- 2026-09-22 Reading moved from unknown to unknown.
- 2026-09-30 Reading moved from unknown to emerging.